Page last updated: 2024-11-12
cgc 11093
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Description
CGC 11093: may prove useful in promoting regression of choroidal neovascularization [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 10026462 |
MeSH ID | M0504976 |
Synonyms (14)
Synonym |
---|
cgc-11093 |
cgc-11098 |
cgc 11093 |
1,2-cyclopropanedimethanamine, n,n'-bis(4-(ethylamino)butyl)-, tetrahydrochloride, (1r,2s)-rel- |
306292-65-9 |
cgc 11098 |
unii-mx8724vfp3 |
3,8,13,18-tetraaza-10,11-((e)-1,2-cyclopropyl)eicosane tetrahydrochloride |
mx8724vfp3 , |
306292-64-8 |
1,2-cyclopropanedimethanamine, n,n'-bis(4-(ethylamino)butyl)-, tetrahydrochloride, (1r,2r)-rel- |
n-ethyl-n'-[[2-[[4-(ethylamino)butylamino]methyl]cyclopropyl]methyl]butane-1,4-diamine;tetrahydrochloride |
n~1~,n~1'~-[cyclopropane-1,2-diylbis(methylene)]bis(n~4~-ethylbutane-1,4-diamine)--hydrogen chloride (1/4) |
DTXSID40952897 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (6)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 6 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 6 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |